{
  "id": 18354841,
  "title": "Oral Sleep Apnea Therapy Poised to Expand Treatment Options",
  "url": "https://urgent.news/2026/11/05/oral-sleep-apnea-therapy-poised-to-expand-treatment-options",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-05T16:06:00.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/oral-sleep-apnea-therapy-poised-to-expand-treatment-options/"
  },
  "original_language": "en",
  "account": "Obstructive sleep apnea—a condition affecting over one billion individuals worldwide and roughly 30 million U.S. residents—currently has no pharmaceutical solution. Continuous positive airway pressure (CPAP) therapy, considered the gold standard, is notoriously uncomfortable and socially embarrassing, leading to high non-compliance rates. Incannex Healthcare, headquartered in Melbourne, Australia, but with offices in New York and Dubai, aims to revolutionize sleep apnea treatment through an oral pharmaceutical therapy.\n\nThe company's lead therapeutic, code-named IHL-42X, is a fixed-dose combination of acetazolamide and dronabinol. Acetazolamide, a carbonic anhydrase inhibitor, induces metabolic acidosis, prompting the body to breathe more frequently. Dronabinol, a synthetic tetrahydrocannabinol, dilates the airways. This dual mechanism reduces apnea episodes during sleep. In Phase II trials, IHL-42X reduced breathing disruption frequency by up to 83%, with 33.3% of low-dose patients and 41.2% of high-dose patients experiencing reductions exceeding 30%.\n\nIHL-42X has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and is expected to generate data from its dose-optimization study, DReAMzz, by mid-2027. The oral nature of the therapy is anticipated to significantly improve patient compliance.\n\nBeyond sleep apnea, Incannex Healthcare is developing two additional therapeutics. For generalized anxiety disorder, PSX-001, a psilocybin-based treatment used in conjunction with cognitive behavioral therapy, showed a 50% reduction in anxiety in 44% of Phase II trial participants. The company's third pipeline asset, for rheumatoid arthritis, is presently on hold while resources focus on the two primary assets.\n\nIncannex Healthcare's strategic expansion includes moving its executive headquarters from Melbourne to Dubai, capitalizing on the UAE's biopharma hub status, fast regulatory approvals, and potential government grants. The company has secured nearly $60 million in funding in the past year, bolstering its financial position and enabling continued development of its promising pipeline.",
  "summary": "An oral obstructive sleep apnea therapy targeting multiple pathways is poised to improve patient compliance and, possibly, outcomes. The post Oral Sleep Apnea Therapy Poised to Expand Treatment Options appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}